Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access

We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Neurocrine Biosciences, Inc. is one of them.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on neurological, neuroendocrine, and neuropsychiatric disorders, continues to demonstrate robust growth through its FDA-approved treatments and advancing pipeline. The company’s portfolio includes key products such as INGREZZA for tardive dyskinesia, therapies for Huntington’s disease chorea, and Orilissa for endometriosis, supported by strategic partnerships with AbbVie and Mitsubishi Tanabe Pharma.

In Q2 2025, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reported revenues of $687.5 million and net income of $107.5 million, exceeding expectations and reflecting strong year-over-year growth. This performance was driven by rising demand for neurology products, expanded payer access, and increased adoption across its portfolio. The business also completed a share buyback, highlighting confidence in its financial position and commitment to returning capital to shareholders.

Looking ahead, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is actively engaging with investors to communicate its growth strategy and pipeline progress. In August 2025, the CEO and investor relations team presented at the Canaccord Genuity 45th Annual Growth Conference, and the company plans to participate in multiple investor events in September. These efforts emphasize transparency and strengthen stakeholder confidence while showcasing ongoing developments in its neurology and neuropsychiatric programs.

While we acknowledge the potential of NBIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.